Veno‐Arterial Extracorporeal Life Support in Heart Transplant and Ventricle Assist Device Centres. Meta‐analysis. (18th December 2020)

• Record Type: Journal Article
• Authors: Kowalewski, Mariusz; Zieliński, Kamil; Gozdek, Mirosław; Raffa, Giuseppe Maria; Pilato, Michele; Alanazi, Musab; Gilbers, Martijn; Heuts, Sam; Natour, Ehsan; Bidar, Elham; Schreurs, Rick; Delnoij, Thijs; Driessen, Rob; Sels, Jan Willem; van de Poll, Marcel; Roekaerts, Paul; Pasierski, Michał; Meani, Paolo; Maessen, Jos; Suwalski, Piotr; Lorusso, Roberto
• Is Part Of: ESC heart failure. Volume 8:Number 2(2021)
• Page Start: 1064
• Page End: 1075
• Publication Date: 2020-12-18
• Subjects: Extracorporeal life support -- Cardiogenic shock -- Acute heart failure -- Meta‐analysis; Heart failure -- Periodicals; 616.129005
• DOI: 10.1002/ehf2.13080
• Languages: English
• ISSNs: 2055-5822

Abstract

Abstract: Aims: Because reported mortality on veno‐arterial (V‐A) extracorporeal life support (ECLS) substantially varies between centres, the aim of the current analysis was to assess the outcomes between units performing heart transplantation and/or implanting ventricular assist device (HTx/VAD) vs. non‐HTx/VAD units in patients undergoing V‐A ECLS for cardiogenic shock. Methods and results: Systematic search according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses was performed using PubMed/MEDLINE databases until 30 November 2019. Articles reporting in‐hospital/30‐day mortality and centre's HTx/VAD status were included. In‐hospital outcomes and long‐term survival were analysed in subgroup meta‐analysis. A total of 174 studies enrolling n = 13 308 patients were included with 20 series performed in non‐HTx/VAD centres (1016 patients, 7.8%). Majority of patients underwent V‐A ECLS for post‐cardiotomy shock (44.2%) and acute myocardial infarction (20.7%). Estimated overall in‐hospital mortality was 57.2% (54.9–59.4%). Mortality rates were higher in non‐HTx/VAD [65.5% (59.8–70.8%)] as compared with HTx/VAD centres [55.8% (53.3–58.2%)], P < 0.001. Estimated late survival was 61.8% (55.7–67.9%) without differences between non‐HTx/VAD and HTx/VAD centres: 66.5% (30.3–1.02%) vs. 61.7% (55.5–67.8%), respectively ( P = 0.797). No differences were seen with respect to ECLS duration, limb complications, and reoperations for bleeding, kidney injury, and sepsis. Yet, weaning rates were higher in HTx/VAD vs. non‐HTx/VAD centres: 58.7% (56.2–61.1%) vs. 48.9% (42.0–55.9%), P = 0.010. Estimated rate of bridge to heart transplant was 6.6% (5.2–8.3%) with numerical, yet not statistically significant, difference between non‐HTx/VAD [2.7% (0.8–8.3%)] as compared with HTx/VAD [6.7% (5.3–8.6%)] ( P = 0.131). Conclusions: Survival after V‐A ECLS differed according to centre's HTx/VAD status. Potentially different risk profiles of patients must be taken account for before definite conclusions are drawn.